Singapore markets closed

Straits Times Index
3,306.02
+6.02(+0.18%)
Nikkei
38,596.47
-36.55(-0.09%)
Hang Seng
18,028.52
-306.80(-1.67%)
FTSE 100
8,237.72
-34.74(-0.42%)
Bitcoin USD
64,363.14
+113.71(+0.18%)
CMC Crypto 200
1,350.90
-9.43(-0.69%)

XNCR Nov 2024 20.000 put

OPR - OPR Delayed price. Currency in USD

Add to watchlist

2.4200

0.0000

(0.00%)

At close: 01:08PM EDT

Simply Wall St.
Xencor (NASDAQ:XNCR) shareholders have endured a 52% loss from investing in the stock five years ago
We think intelligent long term investing is the way to go. But unfortunately, some companies simply don't succeed. For...
Business Wire
Xencor Regains CD20 x CD3 Bispecific T-Cell Engager
PASADENA, Calif., June 13, 2024--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, announced it will regain exclusive worldwide rights to plamotamab, a CD20 x CD3 bispecific T-cell engager, which Xencor advanced through Phase 1 clinical development in hematologic cancers. In 2021, Xencor entered a collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize
Simply Wall St.
Xencor First Quarter 2024 Earnings: Misses Expectations
Xencor ( NASDAQ:XNCR ) First Quarter 2024 Results Key Financial Results Revenue: US$12.8m (down 33% from 1Q 2023). Net...